AUTHOR=Patel Tej H. , Norman Lucas , Chang Steven , Abedi Sina , Liu Catherine , Chwa Marilyn , Atilano Shari R. , Thaker Kunal , Lu Stephanie , Jazwinski S. Michal , Miceli Michael V. , Udar Nitin , Bota Daniela , Kenney M. Cristina 

TITLE=European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects

JOURNAL=Frontiers in Oncology

VOLUME=9

YEAR=2019

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00640

DOI=10.3389/fonc.2019.00640

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of patients but the underlying molecular mechanism(s) are unclear and there are no markers to determine which patients will become resistant. Mitochondria play a significant role not only in energy metabolism but also retrograde signaling (mitochondria to nucleus) that modulates inflammation, complement, and apoptosis pathways. Maternally inherited mitochondrial (mt) DNA can be classified into haplogroups representing different ethnic populations that have diverse susceptibilities to diseases and medications.</p><p><bold>Methods:</bold> Transmitochondrial cybrids, where all cell lines possess identical nuclear genomes but either the H (Southern European) or J (Northern European) mtDNA haplogroups, were treated with cisplatin and analyzed for differential responses related to viability, oxidative stress, and expression levels of genes associated with cancer, cisplatin-induced nephrotoxicity and resistance, apoptosis and signaling pathways.</p><p><bold>Results:</bold> The cisplatin-treated-J cybrids showed greater loss of cell viability along with lower levels of reactive oxygen species and mitochondrial membrane potential compared to cisplatin-treated-H cybrids. After cisplatin treatment, J cybrids showed increased gene expression of <italic>BAX, CASP3</italic>, and <italic>CYP51A</italic>, but lower levels of <italic>SFRP1</italic> compared to untreated-J cybrids. The cisplatin-treated-H cybrids had elevated expression of <italic>CDKN1A/P21</italic>, which has a role in cisplatin toxicity, compared to untreated-H cybrids. The cisplatin-treated H had higher transcription levels of <italic>ABCC1, DHRS2/HEP27</italic>, and <italic>EFEMP1</italic> compared to cisplatin-treated-J cybrids.</p><p><bold>Conclusions:</bold> Cybrid cell lines that contain identical nuclei but either H mtDNA mitochondria or J mtDNA mitochondria respond differently to cisplatin treatments suggesting involvement of the retrograde signaling (from mitochondria to nucleus) in the drug-induced cell death. Varying toxicities and transcription levels of the H vs. J cybrids after cisplatin treatment support the hypothesis that mtDNA variants play a role in the expression of genes affecting resistance and side effects of cisplatin.</p>